Stephens Inc Immuno Gen, Inc. Transaction History

Stephens Inc

  • $6.77 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022
SELL
$4.48 - $6.47 $17,678 - $25,530
-3,946 Reduced 26.8%
10,780 $52,000
Q2 2022

Aug 03, 2022
BUY
$3.15 - $5.76 $425 - $777
135 Added 0.93%
14,726 $66,000
Q1 2022

May 04, 2022
SELL
$4.26 - $7.48 $12,324 - $21,639
-2,893 Reduced 16.55%
14,591 $69,000
Q4 2021

Mar 07, 2022
SELL
$4.75 - $7.5 $22,168 - $35,002
-4,667 Reduced 21.07%
17,484 $130,000
Q3 2021

Oct 27, 2021
SELL
$5.02 - $6.59 $9,136 - $11,993
-1,820 Reduced 7.59%
22,151 $126,000
Q2 2021

Aug 12, 2021
SELL
$5.79 - $8.6 $746 - $1,109
-129 Reduced 0.54%
23,971 $158,000
Q1 2021

May 14, 2021
SELL
$6.5 - $10.53 $20,449 - $33,127
-3,146 Reduced 11.55%
24,100 $195,000
Q4 2020

Feb 10, 2021
SELL
$3.7 - $7.66 $12,876 - $26,656
-3,480 Reduced 11.33%
27,246 $176,000
Q3 2020

Nov 13, 2020
SELL
$3.45 - $4.89 $2,418 - $3,427
-701 Reduced 2.23%
30,726 $111,000
Q2 2020

Aug 24, 2020
BUY
$3.32 - $5.34 $5,524 - $8,885
1,664 Added 5.59%
31,427 $145,000
Q1 2020

May 14, 2020
BUY
$2.12 - $6.8 $381 - $1,224
180 Added 0.61%
29,763 $101,000
Q4 2019

Feb 14, 2020
BUY
$2.25 - $5.8 $4,007 - $10,329
1,781 Added 6.41%
29,583 $151,000
Q3 2019

Oct 18, 2019
SELL
$2.22 - $3.39 $2,084 - $3,183
-939 Reduced 3.27%
27,802 $67,000
Q2 2019

Aug 01, 2019
SELL
$1.8 - $3.3 $2,964 - $5,435
-1,647 Reduced 5.42%
28,741 $62,000
Q1 2019

May 03, 2019
BUY
$2.41 - $5.91 $2,783 - $6,826
1,155 Added 3.95%
30,388 $82,000
Q4 2018

Feb 11, 2019
BUY
$3.94 - $9.7 $2,785 - $6,857
707 Added 2.48%
29,233 $140,000
Q3 2018

Nov 14, 2018
BUY
$8.6 - $11.26 $245,323 - $321,202
28,526 New
28,526 $270,000
Q3 2017

Nov 08, 2017
SELL
$5.4 - $8.47 $207,516 - $325,493
-38,429 Closed
0 $0
Q2 2017

Aug 10, 2017
BUY
N/A
38,429
38,429 $273,000

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Stephens Inc Portfolio

Follow Stephens Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email